A low starting dose of genotropin in growth hormone-deficient adults

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 1, 1997, Pages 129-135

  Janssen, Y J H ^a   Frolich M ^a   Roelfsema, F ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GROWTH HORMONE DEFICIENCY; HORMONAL REGULATION; HORMONAL THERAPY; HORMONE SUBSTITUTION; HORMONE SYNTHESIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE FEEDBACK; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE;

ADULT; AGED; AGING; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; SEX CHARACTERISTICS;

EID: 0031014027     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.1.129     Document Type: Article

References (35)

1. Jørgensen JOL, Pedersen SA, Thuesen L, et al. 1989 Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet. 1:1221-1225.
2. Cuneo RC, Salomon F, McGauley GA, Sönksen PH. 1992 The growth hormone deficiency syndrome in adults. Clin Endocrinol (Oxf). 37:387-397.
3. Bengtsson BÅ, Eden S, Lonn L, et al. 1993 Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab. 76:309-317.
4. De Boer H, Blok GJ, van der Veen EA. 1995 Clinical aspects of growth hormone deficiency in adults. Endocr Rev. 16:63-86.
5. Salomon F, Cuneo RC, Hesp R, Sönksen PH. 1989 The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med. 321:1797-1803.
6. Mårdh G, Lindeberg A, on behalf of the investigators. 1995 Growth hormone replacement therapy in adult hypopituitary patients with growth hormone deficiency: combined clinical safety data from clinical trials in 665 patients. Endocrinol Metab. 2:11-16.
7. Ho KY, Evans WS, Blizzard RM, et al. 1987 Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab. 64:51-58.
8. Iranmanesh A, Lizarralde G, Veldhuis JD. 1991 Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab. 73:1081-1088.
9. Weltman A, Weltman JY, Hartman ML, et al. 1994 Relationship between age, percentage body fat, fitness, and 24-hour growth hormone release in healthy young adults: effects of gender. J Clin Endocrinol Metab. 78:543-548.
10. Veldhuis JD, Liem AY, South S, et al. 1995 Differential impact of age, sex steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay. J Clin Endocrinol Metab. 80:3209-3222.
11. Van den Berg G, Veldhuis JD, Frölich M, Roelfsema F. 1996 An amplitude-specific divergence in the pulsatile mode of GH secretion underlies the gender difference in mean GH concentrations in men and premenopausal women. J Clin Endocrinol Metab. 81:2460-2467.
12. Wollmann HA, Schönau E, Blum WF, Meyer F, Kruse K, Ranke MB. 1995 Dose-dependent responses in insulin-like growth factors, insulin-like growth factor-binding protein-3 and parameters of bone metabolism to growth hormone therapy in young adults with growth hormone deficiency. Horm Res. 43:249-256.
13. Møller J, Jørgensen JOL, Lauersen T, et al. 1993 Growth hormone dose regimens in adult GH deficiency: effects on biochemical growth markers and metabolic parameters. Clin Endocrinol (Oxf). 39:403-408.
14. De Boer H, Blok GJ, Voerman B, de Vries P, Popp-Snijders C, van der Veen EA. 1995 The optimal growth hormone replacement dose in adults, derived from bioimpedance analysis. J Clin Endocrinol Metab. 80:2069-2076.
15. De Boer H, Blok GJ, Popp-Snijders C, Stuurman L, Baxter RC, van der Veen EA. 1996 Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers. J Clin Endocrinol Metab. 81:1371-1377.
16. Holmes SJ, Shalet SM. 1995 Which adults develop side-effects of growth hormone replacement? Clin Endocrinol (Oxf). 43:143-149.
17. Wright AD, Hill DM, Lowy C, Fraser TR. 1970 Mortality in acromegaly. Q J Med. 39:1-16.
18. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R. 1980 Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf). 12:71-79.
19. Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman B, Kjellberg RN, Underwood LE. 1979 Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med. 301:1138-1142.
20. Roelfsema F, Frölich M, van Dulken H. 1987 Somatomedin-C levels in treated and untreated patients with acromegaly. Clin Endocrinol (Oxf). 26:137-144.
21. Zapf J, Froesch ER. 1986 Pathophysiological and clinical aspects of the insulin-like growth factors. Horm Res. 24:160-165.
22. Coulson VJ, Wass JA, Abdulla AF, Cotterill AM, Holly JM. 1991 Insulin-like growth factor binding proteins (IGFBPs) in acromegaly. Growth Regul. 1:119-124.
23. Barkan AL, Beitins IZ, Kelch RP. 1988 Plasma insulin-like growth fartor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab. 67:69-73.
24. Rosenfeld RG, Wilson DM, Lee PD, Hintz RL. 1986 Insulin-like growth factors I and II in evaluation of growth retardation. J Pediatr. 109:428-433.
25. Johannsson G, Bjarnason R, Bramnert M, et al. 1996 The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein, body mass index, age and gender. J Clin Endocrinol Metab. 81:1575-1581.
26. Bates AS, Evans AJ, Jones P, Clayton RN. 1995 Assessment of GH status in adults with GH deficiency using serum growth hormone, serum insulin-like growth factor-1, and urinary growth hormone excretion. Clin Endocrinol (Oxf). 42:425-430.
27. Hoffman DM, O'Sullivan AJ, Baxter RC, Ho KK. 1994 Diagnosis of growth-hormone deficiency in adults. Lancet. 343:1064-1068.
28. Martin JL, Baxter RC. 1992 Insulin-like growth factor binding protein-3: biochemistry and physiology. Growth Regul. 2:88-99.
29. Chin E, Zhou J, Dai J, Baxter RC, Bondy CA. 1994 Cellular localization and regulation of gene expression for components of the insulin-like growth factor ternary binding protein complex. Endocrinology. 134:2498-2504.
30. Cohen P, Fielder PJ, Hasegawa Y, Frisch H, Giudice LC, Rosenfeld RG. 1991 Clinical aspects of insulin-like growth factor binding proteins. Acta Endocrinol (Copenh). 124(Suppl 2):74-85.
31. Hardouin S, Gourmelen M, Noguiez P, et al. 1989 Molecular forms of serum insulin-like growth factor (IGF)-binding proteins in man: relationships with growth hormone and IGFs and physiological significance. J Clin Endocrinol Metab. 69:1291-1301.
32. Albiston AL, Herington AC. 1992 Tissue distribution and regulation of insulin-like growth factor (IGF)-binding protein-3 messenger ribonucleic acid (mRNA) in the rat: comparison with IGF-I mRNA expression. Endocrinology. 130:497-502.
33. Lieberman SA, Mitchell AM, Marcus R, Hintz RL, Hoffman AR. 1994 The insulin-like growth factor I generation test: resistance to growth hormone with aging and estrogen replacement therapy. Horm Metab Res. 26:229-233.
34. Juul A, Main K, Blum WF, Lindholm J, Ranke MB, Skakkebaek NE. 1994 The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol (Oxf). 41:85-93.
35. Jørgensen JOL, Blum WF, Møller N, Ranke MB, Christiansen JS. 1991 Short-term changes in serum insulin-like growth factors (IGF) and IGF binding protein 3 after different modes of intravenous growth hormone (GH) exposure in GH-deficient patients. J Clin Endocrinol Metab. 72:582-587.